Loading clinical trials...
Loading clinical trials...
A Real-world Study on the Addition of Lenalidomide to Reverse Resistance After First-line Treatment Lenvatinib Combined With PD-1 Therapy in Advanced Hepatocellular Carcinoma
Conditions
Interventions
lenalidomide
Locations
1
China
Beijing Tsinghua Changgung Hospital
Beijing, China
Start Date
May 24, 2023
Primary Completion Date
April 30, 2025
Completion Date
April 30, 2025
Last Updated
September 19, 2025
NCT07285850
NCT07106827
NCT06999837
NCT07141056
NCT07132515
NCT06999707
Lead Sponsor
Beijing Tsinghua Chang Gung Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions